GSK Advances mRNA Flu Vaccine to Late-Stage Trials Following Positive Mid-Stage Results
GSK Advances mRNA Flu Vaccine to Late-Stage Trials Following Positive Mid-Stage Results British pharmaceutical giant GSK has announced promising results from a mid-stage trial of its mRNA-based seasonal flu vaccine, marking a key milestone towards late-stage clinical development. The trial demonstrated that the new vaccine candidate elicited strong immune responses against both influenza A and…